Videos
Clinical Conversations by Experts
View all
ASCO GU 2026
- A Phase II Trial of VEGFR-TKI Plus PD-1 Inhibitor in Non-Clear Cell Renal Carcinoma - Jiwei Huang
- PEACE-2 Trial of Cabazitaxel with ADT and Radiotherapy in Very High-Risk Localized Prostate Cancer - Karim Fizazi
- First-in-Human Trial of a Robotic System for Transurethral Bladder Tumor Resection - Jeremy Teoh View all ASCO GU 2026 videos
Featured Videos
Analysis of Genomic Drivers of Discordant Risk Classifications in Prostate Cancer - Michael Zelefsky
Registry Data Shows Risk Migration With Blue Light Cystoscopy - Alireza Ghoreifi & Siamak Daneshmand
PIVOT-006: Phase III Trial of Creto vs Surveillance in Intermediate-Risk Bladder Cancer - Mark Tyson
PEACE-3 Trial Results Show Promise for Radium-223 and Enzalutamide in Asymptomatic mCRPC - Fred Saad
Durvalumab Plus Guadecitabine in Metastatic Kidney Cancer: Phase 1/2 Trial Results - Yousef Zakharia
Access and Utilization of Healthcare by Adults with Spina Bifida - Lindsay Hampson & Alejandro Lopez
Probing the Promising Future of Anti-HER2 Therapies for Micropapillary Bladder Cancer - Jeffrey Ross
Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi
A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore
Management of pN1 Prostate Cancer (Including Systemic Therapy) APCCC 2022 Presentation - Derya Tilki
Access to Advanced Treatments in Landmark Advanced Prostate Cancer Clinical Trials - Bertrand Tombal
The Efficacy and Safety of Olaparib + Abiraterone in the First-Line mCRPC Setting PROpel – Fred Saad
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell
The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris
Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross
DNA Based Markers in High-risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer - Alexander Wyatt
Leaders in Radiopharmaceuticals: Disruptive Innovations and Personal Perspectives
High-Risk Non-Muscle Invasive Bladder Cancer
Treatments in Development in NMIBC
Real-World Decision Making for Treating mHSPC: Case Discussions
Genomic Classifier in Prostate Cancer: Intermediate-Risk
Latest Videos
Recent Conference Coverage
Conference Highlights Written by Physician Scientists
AUA 2026
- AUA 2026: Localized Treatment - The Daily Triage of Grade Group 2 Prostate Cancer
- AUA 2026: Alvimopan in Patients Undergoing Radical Cystectomy and Urinary Diversion on a Standardized Enhanced Recovery After Surgery Protocol: A Randomized, Double-Blind, Placebo-Controlled Trial
- AUA 2026: ENLIGHTED Phase 3 Trial of Non-Thermal, Drug-Activated Padeliporfin Vascular-Targeted Photodynamic Therapy (VTP) for Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC)
Recent Physician-Scientist Review Articles
State of the Evidence Review Articles
Advanced Bladder Cancer
-
The Quickly Evolving Treatment Landscape of Metastatic Urothelial Carcinoma: A New Standard of Care in First-Line Systemic Therapy
Written by Zachary Klaassen, MD, MSc Associate Professor of Urology Urologic Oncologist Medical College of Georgia, Georgia Cancer Center Augusta, GA and Rashid Sayyid, MD, MSc Urologic Oncology Fellow University of Toronto Toronto, Ontario, Canada
-
The Treatment Landscape of Metastatic Urothelial Carcinoma: Second-Line Systemic Therapy
Written by Zachary Klaassen, MD, MSc Associate Professor of Urology Urologic Oncologist Medical College of Georgia, Georgia Cancer Center Augusta, GA and Rashid Sayyid, MD, MSc Urologic Oncology Fellow University of Toronto Toronto, Ontario, Canada
PSMA-Targeted Therapy
-
Beyond a VISION to Making a SPLASH: Advances in PSMA-Based Theranostics in Prostate Cancer
Written by Zachary Klaassen, MD, MSc, Medical College of Georgia, Augusta, Georgia
Transformative Evidence
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
ARANOTE
SES AUA 2026: Darolutamide Plus Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer: Efficacy and Safety by Disease Volume in the Phase 3 ARANOTE Study
Presented by Zachary Klaassen, MD, MSc
The 2026 Southeastern Section of the AUA Annual Meeting featured a presentation by Dr. Zachary Klaassen of a post hoc analysis from the phase 3 ARANOTE trial evaluating darolutamide plus androgen-deprivation therapy (ADT) versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), with outcomes stratified by disease volume. Read More
Genomic Biomarker Testing
ASCO GU 2026: Real-World Patient Characteristics and Treatment Patterns Among Patients with mCRPC Treated with Talazoparib + Enzalutamide in the US
Presented by Pedro C. Barata, MD, MSc
The 2026 ASCO GU Annual Symposium was host to a prostate cancer poster session. Dr. Pedro Barata presented an analysis of real-world patient characteristics and treatment patterns among metastatic castration-resistant prostate cancer (mCRPC) patients treated with talazoparib + enzalutamide in the United States. Read More
Trials in Progress
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
MEVPRO-3 Trial
ASCO GU 2026: MEVPRO-3: Phase III Trial of Mevrometostat + Enzalutamide Versus Placebo + Enzalutamide in mCSPC
Presented by Neeraj Agarwal, MD, FASCO
Neeraj Agarwal, MD, FASCO, discussed MEVPRO-3, a phase III trial of mevrometostat + enzalutamide versus placebo + enzalutamide in mCSPC. Enhancer of zeste homolog 2 (EZH2) enzymatic activity plays a crucial role in prostate cancer progression. Mevrometostat, an oral potent and selective EZH2 inhibitor, may synergize with androgen receptor pathway inhibitors to delay androgen receptor pathway inhibitor resistance. Read More
MEVPRO-1 & 2 Trial
ASCO GU 2026: Efficacy and Safety of Mevrometostat in Combination with Enzalutamide in Patients with mCRPC: Data from a Phase 1 Study
Presented by Nobuaki Matsubara, MD
The 2026 ASCO GU cancers symposium held in San Francisco, CA, was host to the Poster Session A: Prostate Cancer. Dr. Nobuaki Matsubara presented Poster 195: Efficacy and safety of mevrometostat in combination with enzalutamide in patients with mCRPC: Data from a phase 1 study. Read More



